SAN FRANCISCO, CA--(Marketwire - June 09, 2010) - AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products announced today the release of HomStem™, a complete new line of cosmeceutical products, and HairStem™, a topical hair restoration product.
David Stark, President of AmStem International, Inc., said, "These revolutionary products represent the latest innovations in our continuing line of anti-aging, restoration and beauty products."
With the debut of the HomStem™ and HairStem™ line of products last month at the International Beauty Expo in Malaysia, AmStem is nearing readiness to market these products in the United States following voluntary registration with U.S. FDA. The Company is now seeking investigators for its upcoming Institutional Review Board ("IRB") submission of clinical trials later this month, and for informal consumer studies to validate claim testing and to augment marketing efforts worldwide later this year.
"These products will join our flagship product, SteMixx, which is already approved by the Korean FDA, as a 'functional cream' for the treatment of facial skin disfiguration associated with aging such as wrinkles," Stark said. "As soon as final packaging and shipping arrangements have been made and the necessary consumer studies are completed, we expect these products to be available to consumers in the U.S."
The HomStem™ line includes a toner, lotion, essence, neutro cream, eye cream and mist -- all for home use by the consumer for rejuvenation and beautification of the skin. The HairStem™ product is a topical lotion that treats several forms of alopecia (baldness), thickens hair, and prevents dandruff.
Stark said, "While these are unofficial claims until they are validated in the U.S., the history of these products in Korea is such that we expect success. Our team has extensive experience in clinical trials and working with regulatory agencies, so we expect to be able to back up our claims within 90 days, when the first data from the studies is available."
HCSM™, or Human Conditioned Stem Cell Media, is the Company's proprietary version of an accepted ingredient that is derived from proteins secreted by stem cells processed from the Company's own facility, one of the largest umbilical cord blood banks in the world. The cord blood is obtained from consenting donors and is a non-controversial source of stem cells. HCSM™ works by providing the skin with crucial proteins and nutritional supplements to make it healthy, balanced and revitalized in its ability to renew itself. For more information on these products, see the company's web site at http://www.amsteminc.com/amstem-products.
According to industry experts, the U.S. cosmeceutical market is expected to reach $7.6 billion in sales in 2010.
About AmStem Corporation
AmStem Inc. (OTCBB: AMST) is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The Company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The units of cord blood are processed and stored by the Company for use in unrelated transplant, as well as for personal storage and use in the family setting for related transplant and regenerative medicine. The Company has 19 U.S. and international patents related to stem cell processing, application, and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The Company is developing a line of cosmeceutical products based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The Company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio in the clinical treatment of disease, and regenerative medicine areas.
An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
For more information contact AmStem CFO Andrew Norstrud at (813) 283.2556 or Tom Fox at Hawk Associates at (305) 451.1888. For additional information about AMST visit: http://www.amsteminc.com or www.hawkassociates.com.
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.